Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pazopanib With CAPEOX in AGC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who provide written informed consent~* Age over 18 years~* Histologically proven unresectable gastric cancer~* ECOG performance status of 0-2~* At least one uni-dimensionally measurable lesion by RECIST criteria ver 1.1~* Adequate organ system function absolute neutrophil count \> 1,500/µL, platelets \> 100,000/µL, hemoglobin \> 9g/dl Total bilirubin \< 1.5 times upper limit of normal (ULN), AST and ALT \< 2.5 times ULN, PT (INR), PTT \< 1.2 times UNL Serum creatinine less than 1.5 mg/dL or Calculated Ccr at least 50 mL/min, Urine Protein to Creatinine Ratio (UPC) less than 1~* female with Non-childbearing potential~Exclusion Criteria:~* Prior malignancy~* History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug~* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including~* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product~* Presence of uncontrolled infection~* Corrected QT interval (QTc) above 480 msecs using Bazett's formula~* History of any one or more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting, Myocardial infarction, Unstable angina, Coronary artery bypass graft surgery, Symptomatic peripheral vascular disease, Class II or higher congestive heart failure~* Poorly controlled hypertension while on antihypertensive agents~* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months~* Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer~* Evidence of active bleeding or bleeding diathesis~* Hemoptysis within 6 weeks of first dose of study drug~* Any serious and/or unstable preexisting medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures~* Unable or unwilling to discontinue use of prohibited medications listed in the protocol~* Treatment with any of the following anti-cancer therapies;Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib; biologic therapy, immunotherapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib; No prior chemotherapy except adjuvant chemotherapy (Patients who received adjuvant chemotherapy at least 6 months prior to study entry will be allowed regardless of chemotherapeutic regimen~* Pre-existing grade 2 (or higher) motor or sensory neuropathy by CTCAE v4.0~* Known allergy to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib in combination with capecitabine and oxaliplatin (Type: EXPERIMENTAL): Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).